HighMark Wealth Management LLC Grows Stock Holdings in SiBone $SIBN

HighMark Wealth Management LLC raised its holdings in SiBone (NASDAQ:SIBN) by 29.5% in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 24,600 shares of the company’s stock after acquiring an additional 5,600 shares during the period. HighMark Wealth Management LLC’s holdings in SiBone were worth $463,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Palumbo Wealth Management LLC acquired a new position in SiBone in the second quarter valued at $577,000. Harbor Capital Advisors Inc. grew its holdings in SiBone by 7.7% in the 2nd quarter. Harbor Capital Advisors Inc. now owns 573,705 shares of the company’s stock valued at $10,797,000 after buying an additional 40,993 shares during the period. Goldman Sachs Group Inc. increased its stake in shares of SiBone by 28.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 379,757 shares of the company’s stock valued at $5,328,000 after acquiring an additional 83,919 shares during the last quarter. Voya Investment Management LLC increased its stake in shares of SiBone by 26.9% during the 1st quarter. Voya Investment Management LLC now owns 30,818 shares of the company’s stock valued at $432,000 after acquiring an additional 6,526 shares during the last quarter. Finally, Rhumbline Advisers lifted its holdings in shares of SiBone by 3.6% during the 1st quarter. Rhumbline Advisers now owns 59,721 shares of the company’s stock worth $838,000 after acquiring an additional 2,100 shares during the period. Institutional investors and hedge funds own 98.11% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. Wall Street Zen downgraded shares of SiBone from a “buy” rating to a “hold” rating in a report on Saturday, August 9th. Cantor Fitzgerald set a $25.00 price target on shares of SiBone and gave the company an “overweight” rating in a report on Monday, August 11th. Three equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $23.67.

SiBone Stock Up 0.3%

SIBN opened at $14.31 on Friday. SiBone has a 1 year low of $11.70 and a 1 year high of $20.05. The firm has a 50 day moving average price of $15.82 and a 200 day moving average price of $16.26. The company has a debt-to-equity ratio of 0.21, a quick ratio of 7.00 and a current ratio of 8.38. The company has a market cap of $617.33 million, a PE ratio of -25.55 and a beta of 0.83.

SiBone (NASDAQ:SIBN) last released its quarterly earnings data on Monday, August 4th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.05. SiBone had a negative net margin of 12.83% and a negative return on equity of 14.20%. The company had revenue of $48.63 million during the quarter, compared to the consensus estimate of $48.12 million. SiBone has set its FY 2025 guidance at EPS. Sell-side analysts expect that SiBone will post -0.78 earnings per share for the current year.

Insider Activity

In other news, insider Anthony J. Recupero sold 3,833 shares of the company’s stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $15.62, for a total value of $59,871.46. Following the completion of the sale, the insider owned 275,288 shares of the company’s stock, valued at $4,299,998.56. This represents a 1.37% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director John Gordon Freund sold 12,132 shares of the stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $15.99, for a total value of $193,990.68. Following the completion of the sale, the director owned 91,767 shares of the company’s stock, valued at approximately $1,467,354.33. This trade represents a 11.68% decrease in their position. The disclosure for this sale can be found here. Insiders sold 35,148 shares of company stock worth $555,679 in the last quarter. Insiders own 4.00% of the company’s stock.

SiBone Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.